Zimbabwe has declined a major American healthcare agreement worth $367m (£272m) spanning five years due to the United States' insistence on sensitive biological samples.
This move was revealed after a internal memorandum dated December was leaked, which showed Head of State Emmerson Mnangagwa believed the deal was "skewed".
A government representative has since stated that the US was requesting genetic material for research and commercial gain but refused to guarantee the benefits from any future medical innovations.
"We must now begin the difficult and regrettable process of scaling back our health assistance in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy said the US had donated over $1.9bn for health programmes to Zimbabwe over the last two decades.
A doctors' association in Zimbabwe has urged more negotiations to find a deal suitable to all parties so the nation's critical HIV programme can continue.
Broader Implications
This rejection comes after a comparable situation in Kenya, where a high court blocked a similar deal with the US following legal challenges were raised about the security of citizens' medical information.
Since resuming the presidency last year, US President Donald Trump has slashed overseas assistance and closed the key foreign aid agency.
USAID had managed aid for the US government, but Trump argued its expenditure was "wasteful" and his government was pursuing direct bilateral agreements to boost openness and responsibility.
As per reports, Sixteen nations in Africa have so far signed these new agreements, constituting over $18.3bn of fresh investment.
Specifics of the Declined Deal
The money for Zimbabwe would have funded "HIV/Aids treatment and prevention, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"It is our view this partnership could have provided significant benefits for the people of Zimbabwe, particularly the 1.2 million presently receiving HIV treatment via US-supported programmes," Tremont commented.
However, government spokesperson Nick Mangwana argued the arrangement was "asymmetrical".
"The proposal required Zimbabwe to provide its genetic material and health information over an extended period, without any equivalent assurance of benefiting from any scientific breakthroughs – like vaccines, diagnostics, or treatments – that could be developed from that provided information," he stated.
"In essence, our nation would supply the basic resources for medical research with no certainty that the end products would be accessible to our population if a future pandemic arise."
National Interest and Global Health
He also said that the US's withdrawal from the global health body and its pursuit of one-on-one deals were disrupting frameworks already established via the international organization.
Mangwana cited its Pandemic Benefit-Sharing framework designed to manage future pandemics.
"This system is designed to guarantee that when a country contributes its information, the resulting advantages – such as vaccines and treatments – are shared equitably, not monopolised exclusively by those with the funds to create them."
These objections over the US deal "should not be misconstrued as opposition to America," Mangwana stressed.
"We welcome continued discussions with our US partners on how future collaboration might be structured in a manner that honours the independence and interests of both nations."
Health Experts Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) expressed it recognised the official position, but recommended that talks must proceed given that much of the nation's Aids initiatives depended on foreign aid.
"Where technical issues exist, including those involving data governance or agreement terms, these can frequently be resolved via detailed discussion and mutually agreed protections," it commented.
This impasse underscores the ongoing debate between accepting much-needed foreign assistance and protecting local interests in an increasingly data-driven world.